Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).

摘要: @ Background: Imatinib (STI571 or Glivec ® , Novartis) is a new type of tyrosine kinase inhibitor that selectively inhibits various kinases including ABL, BCR-ABL, KIT and PDGF receptors. □ in CML: Earlier studies have shown highly effective the treatment chronic myeloid leukemia (CML), which characterized by translocation chromosome material from 9 to 22 with formation so-called Philadelphia chromosome. During this process, an abnormal fusion protein, formed. In phase I study it was daily dose 300 mg resulted complete hematological response almost 98% patients. GIST: Gastrointestinal stromal tumors (GIST) are also suitable indications for Imatinib, prerequisite being overexpression tumor c-KIT (CD117) This entity responds extremely poorly polychemotherapy. Initial case reports approaches appear indicate GIST promising therapeutic option entity. Follow-up FDG-PET appreciable decrease uptake tissue, some cases within only few days, may well inhibition intratumoral metabolism growth. Most patients metastatic achieve durable responses imatinib, disappearance cancer-related symptoms often rapid. Conclusion: first systemic theapy advanced GIST.